Other languages Curasight A/S

Equities

CURAS

DK0061295797

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
9.96 ^DKK	-1.39%		-1.87%	-43.89%

Apr. 16	Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients	CI
Apr. 12	Curasight A/S Announces Board Changes	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients	Apr. 16
Curasight A/S Announces Board Changes	Apr. 12
Curasight A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22
Curasight A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22
Curasight A/S Announces Acceleration of Therapeutic Strategy to Strengthen Position as A Radiopharmaceutical Theranostic Company	Feb. 13
Curasight Gears Up for Phase II Study in Prostate Cancer	Dec. 22
Curasight A/S Submits Clinical Trial Application for Phase 2 Trial with Utrace	Dec. 18
Curasight A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 23
Curasight A/S Reports Positive Preclinical Results with uTREAT[®] in lung cancer	23-10-18
Curasight A/S Announces Positive Results from the Phase II Study of uTRACE in Brain Cancer Presented at the World Molecular Imaging Congress 2023 in Prague	23-09-14
Curasight A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24
Curasight A/S Announces Positive Results in Upar-Pet/MR Phase II Study in Brain Cancer	23-06-29
Curasight A/S Reports Positive Preclinical Results with uTREAT in Aggressive Brain Cancer (Glioblastoma)	23-06-07
Curasight A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25
Curasight Secures Global License Agreement for Utrace in Prostate Cancer	23-05-11
Curasight A/S Enters into an Exclusive Global License and Collaboration Agreement with Curium Inc	23-05-01
Curasight A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-23
Curasight A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-23
Curasight A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-24
Curasight A/S Initiates Pre-Clinical Studies with uTREAT Therapy in Head and Neck Cancer and Neuroendocrine Tumors	22-10-13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Curasight A/S

Equities

CURAS

DK0061295797

Other languages

Filters